These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 20504250)
21. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy. Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608 [TBL] [Abstract][Full Text] [Related]
22. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer. Boskos CS; Liacos C; Korkolis D; Aygerinos K; Lamproglou I; Terpos E; Stoupa E; Baltatzis G; Beroukas K; Papasavvas P; Dimopoulos MA; Bamias A J Surg Oncol; 2010 Oct; 102(5):408-12. PubMed ID: 19877119 [TBL] [Abstract][Full Text] [Related]
23. Genetic polymorphisms in 5-Fluorouracil-related enzymes predict pathologic response after neoadjuvant chemoradiation for rectal cancer. Nelson B; Carter JV; Eichenberger MR; Netz U; Galandiuk S Surgery; 2016 Nov; 160(5):1326-1332. PubMed ID: 27423551 [TBL] [Abstract][Full Text] [Related]
24. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery. Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921 [TBL] [Abstract][Full Text] [Related]
25. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. Villafranca E; Okruzhnov Y; Dominguez MA; García-Foncillas J; Azinovic I; Martínez E; Illarramendi JJ; Arias F; Martínez Monge R; Salgado E; Angeletti S; Brugarolas A J Clin Oncol; 2001 Mar; 19(6):1779-86. PubMed ID: 11251009 [TBL] [Abstract][Full Text] [Related]
26. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma. Edden Y; Wexner SD; Berho M Colorectal Dis; 2012 May; 14(5):555-61. PubMed ID: 21689364 [TBL] [Abstract][Full Text] [Related]
27. Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. Stoehlmacher J; Goekkurt E; Mogck U; Aust DE; Kramer M; Baretton GB; Liersch T; Ehninger G; Jakob C Cancer Lett; 2008 Dec; 272(2):221-5. PubMed ID: 18722050 [TBL] [Abstract][Full Text] [Related]
28. Rectal cancer adjuvant chemotherapy: when is more useful? Pasetto LM; Basso U; Sinigaglia G; Pucciarelli S; Friso ML; Rugge M; Toppan P; Agostini M; Monfardini S Anticancer Res; 2008; 28(3B):1805-12. PubMed ID: 18630464 [TBL] [Abstract][Full Text] [Related]
30. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Grimminger PP; Danenberg P; Dellas K; Arnold D; Rödel C; Machiels JP; Haustermans K; Debucquoy A; Velenik V; Sempoux C; Bracko M; Hölscher AH; Semrau R; Yang D; Danenberg K; Lenz HJ; Vallböhmer D Clin Cancer Res; 2011 May; 17(10):3469-77. PubMed ID: 21558395 [TBL] [Abstract][Full Text] [Related]
31. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy. Jakob C; Liersch T; Meyer W; Baretton GB; Schwabe W; Häusler P; Kulle B; Becker H; Aust DE Am J Surg Pathol; 2006 Sep; 30(9):1169-74. PubMed ID: 16931962 [TBL] [Abstract][Full Text] [Related]
32. Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma. Lay GC; Caraul B; Dessì M; Orrù S; Murtas R; Deidda MA; Farigu R; Farci D; Maxia L; Casula G; Amichetti M J Exp Clin Cancer Res; 2007 Mar; 26(1):61-70. PubMed ID: 17550133 [TBL] [Abstract][Full Text] [Related]
33. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen. Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506 [TBL] [Abstract][Full Text] [Related]
34. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174 [TBL] [Abstract][Full Text] [Related]
35. Outcome standards for an organ preservation strategy in stage II and III rectal adenocarcinoma after neoadjuvant chemoradiation. Wolthuis AM; Penninckx F; Haustermans K; Ectors N; Van Cutsem E; D'Hoore A Ann Surg Oncol; 2011 Mar; 18(3):684-90. PubMed ID: 20842458 [TBL] [Abstract][Full Text] [Related]
36. Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. Zampino MG; Magni E; Leonardi MC; Petazzi E; Santoro L; Luca F; Chiappa A; Petralia G; Trovato C; Fazio N; Orecchia R; Nolè F; de Braud F Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):421-7. PubMed ID: 19211200 [TBL] [Abstract][Full Text] [Related]
37. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Agostini M; Pucciarelli S; Enzo MV; Del Bianco P; Briarava M; Bedin C; Maretto I; Friso ML; Lonardi S; Mescoli C; Toppan P; Urso E; Nitti D Ann Surg Oncol; 2011 Sep; 18(9):2461-8. PubMed ID: 21416156 [TBL] [Abstract][Full Text] [Related]
38. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer]. Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867 [TBL] [Abstract][Full Text] [Related]
39. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Kim DY; Jung KH; Kim TH; Kim DW; Chang HJ; Jeong JY; Kim YH; Son SH; Yun T; Hong CW; Sohn DK; Lim SB; Choi HS; Jeong SY; Park JG Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):378-84. PubMed ID: 17097835 [TBL] [Abstract][Full Text] [Related]
40. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]